RADNOR, Pa. — November 26, 2025 — Leads & Copy — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company, announced that its Board of Directors’ Compensation Committee granted an inducement stock option award to a new non-executive employee on November 24, 2025.
The award covers 146,000 shares of Mineralys common stock. It was granted under the company’s 2025 Employment Inducement Incentive Award Plan, which allows for equity awards to Mineralys’ new employees.
The option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the vesting commencement date, November 24, 2025. Following this, 1/48th of the total shares will vest each month, contingent upon continued service.
The award was a material inducement for the new employee to join Mineralys, complying with Nasdaq Listing Rule 5635(c)(4).
Mineralys Therapeutics is focused on creating medicines targeting hypertension and related conditions like chronic kidney disease (CKD) and obstructive sleep apnea (OSA), driven by dysregulated aldosterone.
The company’s main product candidate, lorundrostat, is an orally administered, selective aldosterone synthase inhibitor.
Mineralys Therapeutics, founded by Catalys Pacific, is based in Radnor, Pennsylvania.
Investor Relations can be contacted at investorrelations@mineralystx.com.
Source: Mineralys Therapeutics, Inc.
